Civitas Therapeutics
Date | Investors | Amount | Round |
---|---|---|---|
$20.0m | Series A | ||
$8.0m | Series A | ||
N/A | $1.0m | Grant | |
$38.0m | Series B | ||
$55.0m | Series C | ||
Total Funding | €111m |
Recent News about Civitas Therapeutics
EditAcorda Therapeutics, Inc. is a biotechnology company focused on developing and marketing therapies aimed at improving the lives of individuals with nervous system disorders. The company primarily serves patients with multiple sclerosis, spinal cord injuries, and other neurological conditions. Operating within the biopharmaceutical industry, Acorda leverages its deep understanding and experience in nervous system research, product development, and commercialization to bring life-changing therapies to market. The business model revolves around the development, approval, and commercialization of innovative drug therapies, generating revenue through the sale of these pharmaceutical products. Acorda maintains strong relationships with patients, caregivers, healthcare professionals, and investors, ensuring a collaborative approach to healthcare solutions.
Keywords: biotechnology, neurology, multiple sclerosis, spinal cord injury, drug development, commercialization, biopharmaceutical, therapies, nervous system, healthcare.